Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?
[Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].
The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.
Regulation of human glia by multiple sclerosis disease modifying therapies.
Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS.
[Symptoms and clinical manifestations in neuromyelitis optica].
Migration of the Fatigue Symptoms and Impacts Questionnaire-Relapsing Multiple Sclerosis (Fsiq-Rms(tm)) from Paper to an Electronic Diary Format.
The incidence of clinically isolated syndrome in a multi-ethnic cohort.
[Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
[Neuroimmunology: theoretical and clinical aspects].
Reimbursement and market access of multiple sclerosis products in the United States.
A New Approach for Deep Gray Matter Analysis Using Partial-Volume Estimation.
[Progressive Multifocal Leukoencephalopathy with Inflammatory Reactions].
Serum levels of brain-derived neurotrophic factor (BNDF) in multiple sclerosis patients with Trichuris suis ova therapy.
Employment and multiple sclerosis: Policy, programming, and research recommendations.
Acute disseminated encephalomyelitis after treatment of Plasmodium vivax malaria.
Interleukin-17 in human inflammatory diseases.
Delayed nerve stimulation promotes axon-protective neurofilament phosphorylation, accelerates immune cell clearance and enhances remyelination in vivo in focally demyelinated nerves.
Interferon-Beta: Neutralizing Antibodies, Binding Antibodies, Pharmacokinetics and Pharmacodynamics, and Clinical Outcomes.
Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis.
Phase imaging in brain using SWIFT.
[Immunotherapy and infectious issues in multiple sclerosis : Self-injectable and oral drugs for immunotherapy].
Calcium intervention ameliorates experimental model of multiple sclerosis.
Physiological variation of retinal layer thickness is not caused by hydration: A randomised trial.
Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register study.
Pages
« first
‹ previous
…
484
485
486
487
488
489
490
491
492
…
next ›
last »